Related Experiment Video
Updated: Dec 6, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion
Kyungmin Lee1,2, Sang-Hyun Lee1, Wooil Kim1,3
1Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
Abstract:
Anaplastic thyroid cancer (ATC) is a rapidly growing, highly metastatic cancer with limited therapeutic alternatives, thus targeted therapies need to be developed. This study aimed to examine desmoglein 2 (Dsg2) expression in ATC and its biological role and potential as a therapeutic target in ATC. Consequently, Dsg2 was downregulated or aberrantly expressed in ATC tissues. ATC patients with low Dsg2 expression levels also presented with distant metastasis. Dsg2 depletion significantly increased cell migration and invasion, with a relatively limited effect on ATC cell proliferation in vitro and increased distant metastasis in vivo. Dsg2 knockdown induced cell motility through the hepatocyte growth factor receptor (HGFR, c-Met)/Src/Rac1 signaling axis, with no alterations in the expression of EMT-related molecules. Further, specific targeting of c-Met significantly inhibited the motility of shDsg2-depleted ATC cells. Decreased membrane Dsg2 expression increased the metastatic potential of ATC cells. These results indicate that Dsg2 plays an important role in ATC cell migration and invasiveness. Therapies targeting c-Met might be effective among ATC patients with low membrane Dsg2 expression levels, indicating that the analysis of Dsg2 expression potentially provides novel insights into treatment strategies for ATC.
Insights
Desmoglein 2 (Dsg2) downregulation promotes anaplastic thyroid cancer (ATC) metastasis by increasing cell motility via the c-Met pathway. Targeting c-Met may benefit ATC patients with low Dsg2 expression.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor prognosis and limited treatment options.
- Targeted therapies are urgently needed to address the high metastatic potential of ATC.
Purpose of the Study:
- To investigate the expression and function of desmoglein 2 (Dsg2) in ATC.
- To evaluate Dsg2 as a potential therapeutic target for ATC.
Main Methods:
- Analysis of Dsg2 expression in ATC tissues.
- In vitro and in vivo studies involving Dsg2 depletion (knockdown) in ATC cells.
- Investigation of signaling pathways, including hepatocyte growth factor receptor (HGFR, c-Met)/Src/Rac1.
- Assessment of cell migration, invasion, proliferation, and metastasis.
Main Results:
- Dsg2 was downregulated or aberrantly expressed in ATC tissues, correlating with distant metastasis.
- Dsg2 depletion increased ATC cell migration and invasion, with limited impact on proliferation.
- Dsg2 knockdown promoted cell motility via the HGFR (c-Met)/Src/Rac1 axis.
- Targeting c-Met inhibited the motility of Dsg2-depleted ATC cells, and decreased membrane Dsg2 expression enhanced metastatic potential.
Conclusions:
- Dsg2 plays a critical role in regulating ATC cell migration and invasiveness.
- Therapeutic strategies targeting c-Met could be effective for ATC patients with low Dsg2 expression.
- Dsg2 expression analysis may offer novel insights for ATC treatment strategies.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Cell Migration through Invadopodia
Mitogens and the Cell Cycle
Chemotaxis and Direction of Cell Migration

